Genmab ( (GMAB) ) just unveiled an update.
On May 5, 2025, Genmab A/S announced the execution of transactions under its share buy-back program, initiated on March 25, 2025, to repurchase up to 2.2 million shares. The program, aimed at reducing capital and fulfilling commitments under the Restricted Stock Unit program, saw transactions from April 28 to May 2, 2025, accumulating a total of 58,815 shares with a value of over 81 million DKK. This initiative is expected to enhance shareholder value and is set to conclude by July 10, 2025.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance, robust earnings call, and attractive valuation drive a high overall score. The stock’s technical indicators point to moderate upward momentum, but potential overbought conditions warrant caution. Key risks include dependency on major products and competitive pressures.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab is an international biotechnology company based in Copenhagen, Denmark, specializing in innovative antibody therapeutics. Founded in 1999, the company has developed next-generation antibody technology platforms and has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and immune checkpoint modulators. Genmab aims to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: 2.29%
Average Trading Volume: 1,481,087
Technical Sentiment Signal: Buy
Current Market Cap: $13.27B
For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.